Clinical decision making based on radionuclide determined ejection fraction in oncology patients

Journal of Nuclear Medicine

Volumn 38, Issue 5, 1997, Pages 702-705

  William Strauss, H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiotoxicity; equilibrium gated radionuclide angiography; left ventricle ejection fraction

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK ASSESSMENT; SCINTIANGIOCARDIOGRAPHY; TREATMENT CONTRAINDICATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DECISION MAKING; ERYTHROCYTES; EXERCISE TEST; FEMALE; GATED BLOOD-POOL IMAGING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; STROKE VOLUME; TECHNETIUM TC 99M AGGREGATED ALBUMIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030975050     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-153.
2. Speth PAJ, Van Hoesel QGCH, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharm 1988; 15:15-31.
3. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-1117.
4. Black DJ, Livingston RB. Antineoplastic drugs in 1990: a review (part II). Drugs 1990;39:652- 673.
5. Saltiel E, McGuire W. Doxorubicin (adriamycin) cardiomyopathy. West J Med 1983:139:332-341.
6. Shenkenberg TD, VonHoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986:105:67-87.
7. Estorch M, Carrio I, Martinez-Duncker D, et al. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium111 antimyosin monoclonal antibody studies. J Clin Oncol 1993;11:1264-1268.
8. Benjamin RS, Chawla SP, Ewer MS, et al. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 1985;3:117-121.
9. Cassidy J, Merrick MV, Smyth JF, et al. Cardiotoxicity of mitoxantrone assessed by stress and resting nuclear ventriculography. Eur J Cancer Clin Oncol 1988;24:935938.
10. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984;11: (suppl l):54-58.
11. Flor-Weiss D, Uziely B, Muggia F. Protracted drug infusion in cancer treatment: an appraisal of 5FU, doxorubicin-platinums. Ann One 1993;4:723-733.
12. Speyer J, Green M, Zeleniuch-Jacquotte A, Wernz J, Rey M. 1CRF-187 permits long treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10:1 IT127.
13. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-1785.
14. Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of doxil (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin [Abstract]. Proceedings Am SotClin Oncol 1996; 15:303.
15. Hertenstein B, Stefanie M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologie evaluation before transplant. J Clin Oncol 1994;12:998-1004.
16. Baello EB, Ensberg ME, Fergoson DW, et al. Effect of high dose cyclophosphamide and total-body irradiation on left ventricular function in adult patients with leukemia undergoing allogeneic bone marrow transplantation. Cancer Treat Rep 1986;70:11871193.
17. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114.
18. Kimler BF, Mansfield CM, Svoboda DL, et al. Ultrastructural evidence of cardiac damage resulting from thoracic irradiation and anthracyclines in the rat. Int J Radiât Oncol Biol Phys 1984;10:1465-1469.
19. Santos GW, Sensenbrenner LL, Burke PJ, et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 1972;4:559-564.
20. Buckner CD, Rudolph RH, Fefer A, et al. High-dose cyclophosphamide therapy for malignant disease. Cancer 1972;29:357-365.
21. Carmo-Pereira J, Costa FO, Henriques E, et al. Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study. Eur J Cancer Clin Oncol 1988;24:473-476.
22. Villani F, Galimberti M, Crippa F. Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 1989;15:501-506.
23. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K.. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-1056.
24. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10:1 IT127.
25. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58: 607-613.
26. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278283.
27. Twelves CJ, Dobbs NA, Eawrence MA, et al. lododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. BrJ Cancer 1994;69:726-731.
28. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990;8:1806-1810.
29. Danesi R, Marchetti A, LaRocca RV, Bevilacqua G, Del Tacca M. Cardiac toxicity nd antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Cancer Chemother Phamacol 1990;26:403-408.
30. Paracchini ME, Piccinini F, Rossi C, Formelli F. Effect of angiotensin II on the antitumor activity and cardiotoxicity of doxorubicin. Cancer Lett 1990;50:79-85.
31. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Philips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69: 1492-1497.
32. Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: a clinical perspective. Practical Reviews Oncol Hematol 1992;12:231-242.
33. Siveski-Kliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-15.
34. Von Hoff DD, Layard MW, Basa P, et al. Risk factors of doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:710-717.
35. Somlo G, Doroshow JH, Forman SJ, et al. High-dose doxorubicin, etoposide and cyclophosphamide with stem cell reinfusion in patients with metastatic of high-risk primary breast cancer. Cancer 1994;73:1678-1685.
36. Druck MM, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984;53:1667-1674.
37. Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990;5:91-98.
38. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in evaluation of patients being considered for bone marrow transplantation. Bone Marrow Transplant 1990:5:173-177.